Vertex Pharmaceuticals (VRTX) Income from Non-Controlling Interests (2016 - 2018)
Quarterly Income from Non-Controlling Interests fell 1794.27% to -$25.4 million in Q4 2018 from the year-ago period, while the trailing twelve-month figure was -$25.4 million through Sep 2019, down 248.38% year-over-year, with the annual reading at -$9.8 million for FY2018, 94.3% up from the prior year.
Vertex Pharmaceuticals' Income from Non-Controlling Interests history spans 8 years, with the latest figure at -$25.4 million for Q4 2018.
- Income from Non-Controlling Interests came in at -$25.4 million for Q4 2018, down from -$290000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $28.4 million in Q2 2016 to a low of -$188.3 million in Q3 2017.
- The 5-year median for Income from Non-Controlling Interests is -$98000.0 (2015), against an average of -$10.7 million.
- Year-over-year, Income from Non-Controlling Interests skyrocketed 5741.84% in 2016 and then tumbled 26956.75% in 2017.
- Vertex Pharmaceuticals' Income from Non-Controlling Interests stood at $4.2 million in 2014, then plummeted by 122.39% to -$938000.0 in 2015, then crashed by 452.88% to -$5.2 million in 2016, then skyrocketed by 128.94% to $1.5 million in 2017, then tumbled by 1794.27% to -$25.4 million in 2018.
- Per Business Quant, the three most recent readings for VRTX's Income from Non-Controlling Interests are -$25.4 million (Q4 2018), -$290000.0 (Q3 2018), and -$1.1 million (Q2 2018).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -13.75 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | - |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | - |
| 10 | Revolution Medicines | 30.42 Bn | 30.42 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | -25.43 Mn |
| Sep 30, 2018 | -290,000.00 |
| Jun 30, 2018 | -1.11 Mn |
| Mar 31, 2018 | 17.04 Mn |
| Dec 31, 2017 | 1.50 Mn |
| Sep 30, 2017 | -188.32 Mn |
| Jun 30, 2017 | 13.17 Mn |
| Mar 31, 2017 | 1.79 Mn |
| Dec 31, 2016 | -5.19 Mn |
| Sep 30, 2016 | -696,000.00 |
| Jun 30, 2016 | 28.37 Mn |